Condition
Unresectable Skin Squamous Cell Carcinoma
Total Trials
4
Recruiting
3
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 2 (1)
Trial Status
Recruiting3
Active Not Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT05896839Phase 1Recruiting
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
NCT05269381Phase 1Recruiting
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT02721732Phase 2Active Not Recruiting
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
NCT05085496Phase 1Recruiting
Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC
Showing all 4 trials